Sebolt-Leopold J - Search Results

1

3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.

Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, Blasberg R, Sebolt-Leopold J, Larson S, Rosen N. Solit DB, et al. Cancer Res. 2007 Dec 1;67(23):11463-9. doi: 10.1158/0008-5472.CAN-07-2976. Cancer Res. 2007. PMID: 18056475 Free PMC article.

2

BRAF mutation predicts sensitivity to MEK inhibition.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. Solit DB, et al. Nature. 2006 Jan 19;439(7074):358-62. doi: 10.1038/nature04304. Epub 2005 Nov 6. Nature. 2006. PMID: 16273091 Free PMC article.

3

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

Allen LF, Sebolt-Leopold J, Meyer MB. Allen LF, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16. doi: 10.1053/j.seminoncol.2003.08.012. Semin Oncol. 2003. PMID: 14613031 Review.

4

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway.

Sebolt-Leopold JS. Sebolt-Leopold JS. Clin Cancer Res. 2008 Jun 15;14(12):3651-6. doi: 10.1158/1078-0432.CCR-08-0333. Clin Cancer Res. 2008. PMID: 18559577

5

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.

Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF 3rd, Conaway M, Weber MJ. Gioeli D, et al. Mol Cancer Ther. 2011 Sep;10(9):1581-90. doi: 10.1158/1535-7163.MCT-10-1033. Epub 2011 Jun 28. Mol Cancer Ther. 2011. PMID: 21712477 Free PMC article.

6

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.

Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS. Ziemke EK, et al. Clin Cancer Res. 2016 Jan 15;22(2):405-14. doi: 10.1158/1078-0432.CCR-15-0829. Epub 2015 Sep 14. Clin Cancer Res. 2016. PMID: 26369631 Free PMC article.

7

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Lorusso PM, et al. J Clin Oncol. 2005 Aug 10;23(23):5281-93. doi: 10.1200/JCO.2005.14.415. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009947 Clinical Trial.

8

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.

Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J. Williams TM, et al. Mol Cancer Ther. 2012 May;11(5):1193-202. doi: 10.1158/1535-7163.MCT-12-0098. Epub 2012 Mar 12. Mol Cancer Ther. 2012. PMID: 22411900 Free PMC article.

9

Deciphering the Complexity of MEK Mutations in the Clinic.

Whitehead CE, Sebolt-Leopold JS. Whitehead CE, et al. Among authors: sebolt leopold js. Cancer Res. 2020 Oct 1;80(19):4042-4043. doi: 10.1158/0008-5472.CAN-20-2611. Cancer Res. 2020. PMID: 33008803

10

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Haigis KM, et al. Nat Genet. 2008 May;40(5):600-8. doi: 10.1038/ng.115. Epub 2008 Mar 30. Nat Genet. 2008. PMID: 18372904 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters